Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
New deals are flooding into the European securitization market, especially the UK, in the last week of January, after two RMBS issues attracted unprecedented demand. Issuers are betting investors remain hungry for securitized products, despite national lockdowns. -
Direct lenders and debt funds have always pitched themselves as being more suitable partners for businesses than banks, bondholders, or other institutional lenders. When the going gets tough, they can be quicker to waive covenants and offer new money than a less concentrated creditor group. But this also puts them in pole position to take the keys from a business should things go wrong — which we may see happen this year.
-
JD Sports, the UK sporting equipment retailer, is looking at the possibility of raising equity capital to help it through the next few months of Covid-19 lockdowns and to take advantage of investment opportunities in the future.
-
CureVac, the German biotechnology company, has launched a $523m share sale to fund late stage clinical trials for its Covid-19 vaccine, and an expansion of its manufacturing capacity.
-
Chinese healthcare duo MicroPort CardioFlow Medtech Corp and Suzhou Basecare Medical Corp have kicked off their Hong Kong IPOs after a week of pre-marketing.
-
Fitch Ratings is poised to revise most of its CLO tranches outlooks from negative to stable, following a revision of its CLO coronavirus stress scenario, which is considered no longer representative of the near-term risks for CLOs.
